• J. Cardiothorac. Vasc. Anesth. · Sep 2020

    In Vivo Protamine Titration Using Activated Coagulation Time to Neutralize Heparin Anticoagulation in Cardiac Surgery: Proof of Concept.

    • Antoine G Rochon, Sylvain Bélisle, Pierre Couture, Annik Fortier, Jean-Sébastien Lebon, and Alain Deschamps.
    • Department of Anesthesia, Montreal Heart Institute, Montreal, Quebec, Canada. Electronic address: antoinerochon@me.com.
    • J. Cardiothorac. Vasc. Anesth. 2020 Sep 1; 34 (9): 2369-2374.

    ObjectiveIn vivo protamine titration (IVPT) is based on the observation of a plateau on the decay curve of the celite activated clotting times (ACTs) during protamine infusion for heparin reversal. The aim of the present study was to determine the optimal protamine/heparin ratio to reverse anticoagulation using IVPT curves.DesignProspective, randomized study.SettingTertiary care university hospital.ParticipantsThe study comprised 138 patients undergoing elective cardiac surgery requiring cardiopulmonary bypass.InterventionsThe control group was given a protamine infusion of 1.3 mg per 1 mg (100 U) of heparin over 21 minutes. ACT was measured every 3 minutes. In the test group, the protamine dose was prepared using the same ratio as for the control group, and ACT values were measured every 3 minutes until a plateau was reached (2 consecutive ACT values <160 s), at which time the protamine infusion was stopped. The protamine/heparin ratio, blood losses, transfusions, and heparin concentrations were recorded.ResultsThe protamine dose was lower in the test group (456.00 ± 105.66 mg [control group] v 295.25 ± 100.60 mg [test group]; p < 0.0001). The mean protamine/heparin ratios were 1.30 ± 0.10 (control group) and 0.81 ± 0.22 (test group) (p < 0.0001). Heparin concentrations were greater in the test group 15 minutes (0.10 [0-0.2] U/mL v 0 [0-0.1] U/mL; p = < 0.0001) and 3 hours (0 [0-0.1] U/mL v 0 [0-0] U/mL; p = 0.0002) after protamine infusion. There was no difference in the blood losses and transfusion requirements.ConclusionsIVPT is safe and efficient in this low-risk population.Copyright © 2020 Elsevier Inc. All rights reserved.

      Pubmed     Full text   Copy Citation  

      Add institutional full text...

    Notes

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.